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REPORTS 
Cell-Mediated Immunity in Untreated and PUV A Treated Atopic 
Dermatitis 
E. SOPPI, M.D., M. VIANDER, M.D., A.-M. SOPPI, B.M., AND C_ T. JANSEN, M.D. 
Departments of M edical Microbiology and Dermatology, University of Turku, TurlUl, FI:nland 
In 22 adult patients with atopic dermatitis, lymphocyte 
subpopulation counts, mitogenic responses to several 
PHA and Con A concentrations, nonspecific mitogen 
induced, and indomethacin sensitive suppressor cell 
functions and leukocyte migration inhibitory factor pro-
duction were investigated. Patients with severe atopic 
dermatitis had normal PHA and Con A responses, al-
though somewhat lower than matched controls, while 
mild AD patients equalled controls in this respect. No 
significant differences between AD patients and controls 
were detected with respect to lymphocyte subpopula-
tions, suppressor cell function or leukocyte migration 
inhibitory factor production. Methoxalen plus ultravi-
olet light (PUV A) therapy induced significant clinical 
improvement in 9 out of 10 treated patients. A concomi-
tant decrease of the mitogenic responses and increase of 
the Con A induced nonspecific suppressor cell activity 
was recorded, while other immunological parameters 
remained unaffected by the therapy. Thus PUVA ther-
apy induces both local clinic.al and systemic immunolog-
ical manifestations. The possibility that the observed 
immunological changes would be operative in the PUV A 
induced healing process, however, seems unlikely, as the 
present study did not disclose any obvious relationship 
between immune parameters and severity of atopic der-
matitis. 
A variety of reported immunological defects in atopic der-
matitis (AD), e.g., low levels of lymphocyte subpopulations [1-
7] and their unpaired functional activity [1,8-16] are still mat-
ters of controversy [2,11,16-18]. As many investigators have 
employed only one test in the chamcterization oftheu· patients, 
the possible parallel existence of different inununological ab-
normalities in AD has been inadequately examined; the rela-
tionship of possible abnormalities to the severity of atopic 
dermatitis is also still insufficiently documented. Thus far, there 
is no satisfactory systemic medication for atopic dermatitis and 
topical corticosteroids are the mainstay of treatment. However, 
therapy with 8-methoxypsoralen and ultraviolet (UV -A) radia-
tion has recently been introduced as an effective treatment of 
AD [19]. 
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Abbreviations: 
AD: atopic dermatitis 
ESI: extent of skin involvement 
FCS: fetal calf serum 
HBSS: Hanks' balanced salt solution 
LMIF: leukocyte migration inhibitory factor 
SI: severity indices 
SIg: surface immunoglobulill positive cells 
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In the present investigation we have carried out an extensive 
immunological analysis of 22 adult patients with atopic der-
matitis and of 13 matched controls. To the best of our knowl-
edge this is the first report where, in addition, the immunolog-
ical status of AD patients before and after PUV A treatment is 
compared. 
MATERIALS AND METHODS 
Patients and Controls 
Twenty-two adult male patients suffering from long-standing atopic 
dermatit is of sufficient severity to cause a referral to the Department 
of Dermatology were invited in the study. The diagnosis of atopic 
dermatitis (AD) was confirmed uSllg the criteria of Hanifin and Lobitz 
Jr. [18). The extent of skin involvement (ESI, 5-60%) and the degree of 
inflammation (1-3) as well as the severity indices (SI, extent of Skill 
involvement X degree of inflammation, 5-180) were used for subgroup-
ing the patients: mild atopic dermatit is (ESI: 5-40% and SI: 5- 40) and 
severe atopic dermatitis (ESI: 30- 70% and SI: 50-180). Fifteen patients 
and 8 patients had mild rhinitis and asthma without any treatment, 
respectively. Thirteen healthy age- and sex-matched subjects with 
negative history for atopy were studied as parallel controls. 
Blood Samples and Lymphocyte Subpopulations 
Fifty milliliters of heparinized (50 IU/ ml) venous blood was obtained 
from each subject between 8 and 10 A.M. No specific drugs were used 
for 72 hr prior to the study, and any topical corticosteroid application 
was avoided during a one-week period before taking the samples. The 
mononuclear cells were isolated on a Ficoll-Isopaque (Pharmacia Fine 
Chemicals, Uppsala, Sweden) density gradient [20) and washed thrice 
with Hanks' balanced salt solu t ion at 22°C. After washes, more than 
95% of cells were mononuclear , and theil· viability exceeded 90%, as 
determined by trypan blue (0.25%) exclusion test. 
T lymphocytes were estimated by an E-rosette test according to 
Jondal, Holm, and Wigzell [21). The number of suppressor cells was 
estimated using the ability of theophylline to inhibit the E-rosette 
formation of human lymphocytes [22,23). Surface immunoglobulin 
positive cells (SIg) were determined as described eru·lier [24). 
Lymphocyte Transformation 
H epru·inized whole blood was diluted 1:7 with RPM! 1640 (Grand 
Island Biological Co., Grand Island, N. Y .) and used for lymphocyte 
stimulation as described eru·lier [25-26), with slight modifications. In 
brief, 175 iLl of blood-RPMI mixture was placed into flat-bottom wells 
of a mictotiter plate (Micro T est II, Falcon Plastics, Oxnru·d, Calif.) . 
Thereafter, the mitogens were added in 25 ILl of RPMI 1640. Control 
cultures received 25 1'1 of plain medium. The final concentrations of 
PHA (PHA M, Difco Laboratories, D etroit, Mich.) were 5, 25, 125,625, 
and 1250 I'g/ Inl, those of concanavalin A (Con A, Phru·macia) were 1, 
5, 25, 125, and 625 I'g/ ml. The total incubation t ime for PHA and Con 
A stimulated cultures was 96 lu·. Eighteen hr before hru"Vestmg, 20 iLl of 
125I-labeled 5-iodo-2'-deoxyuridine (1251UdR) (0.25 I'Ci, sp. act. 90-110 
mCi/mg, The R adiochemical Centre, Amershrun, England) was added 
into each well together with 5-fluoro-2'-deoxyuridine to increase the 
uptake of 125IUdR [27]. All counts given have been corrected to the 
reference day of 125IUdR. 
Suppressor Cell Assays 
For mitogen-induced suppressor cells, the method of Shou, Schwrutz, 
and Good [28] and Hallgren and Yunis [29] was used with slight 
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modifications [30). In brief, 2 x 10" isolated mononuclear cells in one 
ml of RPMI 1640 with 10% human AB serum were incubated for 48 hI' 
with PHA M (125 (.Ig/ ml) , Con A (40 (.Ig/ml), or without any mitogens. 
For the last 30 min of the incubation, mitomycin C ("15 (.Ig/ml, Sigma, 
Saint Louis, Mo.) was added to arrest cell proliferation. Thereafter, the 
cells were washed 3 times with Hanks' balanced salt solution (HBSS) 
and once with RPMI 1640 and the number of viable cells was deter-
mined by trypan blue exclusion test. The cell density was adjusted to 
2 x 10"/ml in RPMI 1640. Five X 10' mitogen- induced suppressor or 
control cells in 25 (.Il of RPM I 1640 were mixed with allogeneic responder 
cells (10 (.Il of whole blood + 40 (.Il of RPMI 1640) in round-bottom wells. 
The cultures were stimulated with PHA M (125 (.Ig/ml) or Con A (40 
(.Ig/ml). After 48 hr of incubation the cultures were processed as 
described above. 
To estimate the activity of the prostaglandin-producing suppressor 
cells [31,32], indomethacin, dissolved in 100% ethanol, was added into 
whole blood cultures to inhibit the prostaglandin production of sup-
pressor cells. The final concentration of indomethacin in the cultures 
was 1 (.Ig/ml. The control cultures received an equal volume of ethanol 
(final amount 0.01% in cu ltures), which is known to be without any 
effect [31). 
Leulwcyte Migration Inhibitory Factor (LMIF) Production 
To evaluate the production of leukocyte migration inhibitory factor 
(LMIF) , 2 X 10" isolated mononuclear cells in one ml of RPMI 1640 
with 10% FCS (Gibco) were incubated for 72 hr with PHA M (125 (.Ig/ 
ml), Con A (40 (.Ig/ml), PPD (12.5 (.Ig/ml) and PWM (1:500). As a 
control, a mitogen-free culture was included in each test. At the end of 
the incubation the cultures were pelletted (10 min, 200 g ) and the 
supernatants were tested for LMIF activity by the agarose migration 
method using human granulocytes as indicator cells as described by 
Clausen [33] and Rasanen, Karhumaki, and Krohn [34]. The migration 
index was calculated as follows: 
area of migration in the presence of test supernatant 
MI= f" I area 0 mIgratIOn in the presence of contro supernatant 
PUVA Therapy 
After the initial immunological assessment, 10 patients entered 
PUV A treatment. The patients were treated 3 times a week for a total 
of 13-26 times with oral 8-methoxalen (0.6 mg/kg) and with increasing 
doses of UVA irradiation for total doses 51-146 J /cm2 • The patients 
were tested 2 days after the last treatment of PUV A therapy. 
Statistics 
Student's t-test, paired t-test, and split-plot type analysis of variance 
were used for estimation of significance. 
RESULTS 
Pre-therapy Evaluations 
No differences were observed in the number of leukocytes 
and lymphocyte subpopulation counts between controls and 
patients with mild or severe AD (Table I). Lymphocyte trans-
formations induced by Pl{A and Con A were similar in controls 
and in mild AD patients (Fig 1) . In severe AD patients lympho-
cyte blastogenesis was lower than in controls, particularly at 
optimal and supraoptimal Con A concentrations of mitogens 
(Fig 1), but the differences were not statistically significant. In 
unstimulated cultures severe and mild AD patients had higher 
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spontaneous proliferation (369 ± 238 cpm and 330 ± 214 cpm; 
p < 0.05 and N .S., respectively) than their matched controls 
(226 ± 170 cpm). 
PHA, Con A, and PPD induced suppressor cell activities 
were normal in all groups. Although somewhat lower values 
were recorded in severe as compared to mild dermatitis pa-
tients, the differences were not significant (Table Il) . The 
activity of indomethacin sensitive (prostaglandin producing) 
suppressor cells was studied in 9 AD patients. The augmenta-
tion indices (ratio of cpm in mitogen stimulated cultures with 
indomethacin to cpm in mitogen stimulated cultures without 
indomethacin) were lower in AD patients than those in controls 
suggesting decreased activity of prostaglandin producing sup-
pressor cells, but the differences were not significant. The 
augmentation indices for PHA (25, 125 and 625 fLg/ml) stimu-
lation were 0.85 ± 0.35, 0.91 ± 0.31 and 0.90 ± 0.50 in AD 
patients and 1.10 ± 0.31, 1.06 ± 0.20 and 1.13 ± 0.39 in controls 
(N = 13). The indices for Con A (5, 25, and 125 fLg/ml) 
stimulation were: AD patients, 0.89 ± 0.52, 0.92 ± 0.37 and 0.72 
± 0.30 and controls (N = 13), 1.22 ± 0.30, 1.10 ± 0.24 and 1.17 
± 0.50, Mitogen-induced LMIF production of lymphocytes was 
equal in controls and in all AD patients (Table III). Finally, no 
correlation in any of the immunological functions with the 
severity of AD was found. 
Effects of PUVA Therapy 
Most patients improved considerably during the PUVA treat-
ment and in 2 patients a total recovery was registered. In one 
patient the therapy had no effect. PUV A therapy had no effect 
on the number of leukocytes and lymphocyte subpopulation 
counts (Table I), but a significant (p < 0.001) decrease of 
mitogenic responses induced by the supraoptimal concentration 
(1,250 fLg/ml) of PHA was observed (Fig 2). In Con A response 
the same tendency was seen when suboptimal and optimal 
concentrations of Con A were used (0.1 > P > 0.05) (Fig 2). 
PUV A treatment had no marked effect on the spontaneous 
proliferation: 322 ± 155 cpm before and 370 ± 194 cpm after 
therapy. 
The Con A and PWM induced suppressor cell activities were 
significantly higher (p < 0.01) after PUV A therapy than before. 
The same phenomenon was also seen in 2 out of 9, and 5 out of 
9 patients in PHA and PPD induced suppressor cell activities, 
respectively (Table II). After PUVA therapy an increasing 
tendency for LMIF production induced by PHA, Con A and 
PWM (0.1 > p > 0.05 in Con A induced LMIF production) was 
also observed (Table III). 
DISCUSSION 
Our material represents a rather homogenous sample of 
young adult patients with atopic dermatitis. As could be antic-
ipated, bronchial asthma and allergic rhinitis were associated 
features in some of the cases. However, the respiratory symp-
toms in our patients were always mild or moderate, and of 
seasonal occurrence. At the time of the study, the majority of 
the patients needed no drug therapy for rhinitis and none took 
TABLE 1. The number of leuhocytes and lymphocyte subpopulations and the effect of PUVA therapy in patients with mild and severe atopic 
dermatitis and in matched controls 
Subjects Leukocytes E-rosette fonning Theophylline S-lg-positive Lymphocytes sensitive E-rosette 
cells forming cells cells 
Matched controls (N = 13) 6686 ± 1598 3100 ± 1149 1921 ± 779 819 ± 494 225 ± 310 
Mild dermatitis (N = 12) 6776 ± 1972 3105 ± 1277 1862 ± 660 1013 ± 433 427 ± 441 
Severe dermatitis (N = 10) 6620 ± 2493 2685 ± 887 1726 ± 463 1047 ± 313 137 ± 108 
Treatment . 
Before PUV A therapy (N = 9) · 6422 ± 1113 2977 ± 923 1902 ± 663 1152 ± 383 273 ± 166 
After PUV A therapy (N = 9) 7200 ± 2381 2975 ± 304 1896 ± 304 1020 ± 405 228 ± 185 
Mean number ± SD of ceLIs (x 10"/1) is given. 
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FIG . 1. PHA and Con A responses in non-atopic controls 0, patients with mild ImJ, and severe . atopic dermatitis. Net counts per minute (cpm) 
are given (= cpm with mitogen minus cpm without mitogen). Split-plot type analysis of variance is lIsed for estimation of significance. 
TABLE II. The activity of PHA, Con A and PPD induced suppressor cells and the effect of PUVA therapy in patients with m.ild or severe 
atopic dermatitis and in matched controls 
Effect of PHA induced suppressor Effect of Con A induced suppressor Effect of PPD induced suppressor 
Subjects cells on Initogenic respon e to cells on mitogenic response to cells on mitogenic response to 
PHA Con A PWM PHA Con A PWM PHA Con A PWM 
Matched controls (N = 13) 65 ± 18 75 ± 15 70 ± 24 43 ± 20 59 ± 18 52 ± 31 33 ± 18 36 ± 17 31 ± 30 
Mild dermatitis (N = 12) 71 ± 21 57 ± 30 69 ± 30 49 ± 40 59 ± 40 60 ± 20 27 ± 30 22 ± 32 28 ± 33 
Severe dermatitis (N = 10) 61 ± 22 65 ± 21 57 ± 22 48 ± 11 57 ± 17 58 ± 55 21 ± 16 23 ± 23 27 ± 26 
Treatment 
Before PUV A therapy (N = 9) 56 ± 24 49 ± 26 67 ± 42 46 ± 12 53 ± 19 40 ± 28 23 ± 23 24 ± 25 30 ± 29 
After PUV A therapy (N = 9) 43 ± 30 46 ± 39 89 ± 23 47 ± 22 76 ± 13" 79 ± 17" 35 ± 50 47 ± 61 58 ± 48 
Mean suppression percent ± SD is presented. 
" = p < 0.01 (paired t-test). 
TABLE III. The PHA, Con A, PWM and PPD induced leulwcyte migration inhibitory factor (LMIF) production and the effect of PUVA 
therapy in patients with mild or severe atopic dermatitis and in m.atched controls 
Subjects 
LMIF production induced by 
PHA Con A PWM PPO 
Matched controls (N = 12) 0.62 ± 0.18 0.42 ± 0.14 0.54 ± 0.20 0.53 ± 0.15 
Mild dermatitis (N = 10) 0.56 ± 0.19 0.39 ± 0.14 0.49 ± 0.15 0.51 ± 0.29 
Severe dermatitis (N = 9) 0.68 ± 0.26 0.42 ± 0.16 0.69 ± 0.14 0.41 ± 0.10 
Treatment 
Before PUV A therapy (N = 6) 0.61 ± 0.35 0.36 ± 0.15 0.60 ± 0.15 0.37 ± 0.08 
After PUV A therapy (N = 8) 0.52 ± 0.24 0.26 ± 0.16 0.48 ± 0.18 0.37 ± 0.17 
Mean migration index ± SD is given. Migration index is expressed as percent fTom area that human granulocytes have been migrated without 
mitogens. 
medication for asthma. Thus the contribution of these symp-
toms to the immunological findings is probably negligible. 
The observation that the number of leukocytes and lympho-
cyte subpopuJation counts were equal in controls and in AD 
patients agrees with several previous reports, but disagrees with 
investigations describing a decreased percentage or absolute 
number of T cells in assays omitting fetal calf serum (FCS) 
(reviewed by Byrom and Timlin) [2]. This discrepancy has 
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FIG. 2. The effect of methoxalen plus ultraviolet ligh t (PUVA) therapy on the PHA and Con A responses in AD patients; 0 = before therapy, 
• = after therapy. N et counts per minute (epm) are given (= cpm with mitogen minus cpm without mitogen) . •• • = p < 0.001. Paired I -test is 
used for es timation of significance. 
been assumed to result from a normalization of the rosette-
forming capacity of T cells by thymic hormone in FCS [2,35]. 
We have used FCS in our assay, and this may explain the 
normal T cell number of our AD patients. A reduction of Ty 
(suppressor) cell number has been described in asthma and 
severe rhinitis [3-5, 36], and in active atopic dermatitis [7], but 
not in allergic rhinitis [5]. In our patients, the number of the 
theophylline sensitive rosette-forming lymphocytes which are 
known to contain Ty suppressor cells [23] were normal. Re-
cently, using monoclonal antibodies, a reduced percentage of 
total T cells as well as T suppressor-cytotoxic cells in atopic 
dermatitis has been described [6]. In the present study PHA 
and Con A induced lymphocyte blastogenesis in matched con-
trols did not differ from that in mild atopic dermatitis. In severe 
AD patients PHA and Con A responses were somewhat lower 
than control values when optimal and supraoptimal concentra-
tions were used, respectively (Fig 1) . Likewise, Rachelefsky and 
Thestrup-Pedersen reported decreased responses to suboptimal 
doses of PHA [10,11] while conflicting results have been ob-
served with Con A stimulation. Thestrup-Pedersen et al [11] 
reported increased and Schopf et al [12] decreased responses to 
suboptimal Con A concentrations. The findings support an 
imbalance between PHA and Con A reactive lymphocyte sub-
populations with variable expression in different subgroups of 
AD patients. The increased spontaneous lymphocyte prolifer-
ation in our AD patients is in agreement with previous studies 
and may reflect a deficiency of regulator T cell functions [11, 
12]. . 
In agreement with the present findings, normal mitogen-
induced suppressor cell function has been previously reported 
in AD patients [13,15,37], allergic rhinitis and asthma [38], 
although this has been recently challenged in AD patients by 
Strannegard and Stingl et al [1,7]. Stingl et al stresses that cells 
from AD patients with wide-spread clinical involvement could 
not be educated to express suppressor signals as effectively as 
could cells from clinically inactive patients or normal healthy 
individuals [7]. However no such finding was observed in the 
present investigation and furthermore, the activity of indo-
methacin sensitive, prostaglandin-producing suppressor cells in 
AD patients did not markedly differ fTom that in controls; this 
finding corroborates the results of earlier reports [13,15,39]. 
However, additional suppressor cell populations obviously exist 
and recently Strannegard has reported that some AD patients 
have defective adherent suppressor cells [39]. 
The 2-stage (indirect) technique for LMIF production corre-
lates well with skin test reactivity in humans [40,42]. Using this 
technique Horsmanheimo et al observed a sign ificant decrease 
in both PHA and Con A induced LMIF production in AD 
patients (including children) [14,43]. The discrepancy between 
their and our present findings is difficult to explain. Thestrup-
Pedersen et al have reported PPD induced LMIF production 
to be eq ual in normal and AD patients [11]. The high sensitivity 
of the 2-stage LMIF assay for detecting cellular immunodefi-
ciencies has been demonstrated by Gorski et al [44]. The normal 
results obtained in the present study indicate that in AD 
patients no major cellular immunodeficiency is found. 
Recently PUV A h as been introduced in the treatment of 
atopic dermatitis [19]. The good clinical effect ofPUVA therapy 
in AD, also noted in the present study, may reflect the effect of 
PUV A on local immunologic processes [45,46]. The possibility 
of systemic immunologic effects has been demonstrated in 
animal experiments, in which PUVA has been shown to induce 
systemic immunosuppression [47]. In our patients, PUV A treat-
ment increased Con A and PWM induced suppressor cell func-
Oct. 1982 
tion and decreased mitogenic r esponses. Diminished niltogenic 
responses have earlier been observed in PUV A treated psoriatic 
patients [48,49] , the immune system of which is considered to 
be basically a bnormal [49]. 
The increasing trend in LMIF production after PUVA is a n 
interesting finding. However, LMIF production was clearly 
normal prior to treatment in our patients, both in severe and 
mild cases. Thus the data do not support the significance of 
LMIF production as an indicator of disease activity in AD 
patients as suggested by Horsmanheimo et al [14, 43]. 
It is not clear whether the immunological changes r ecorded 
dw-ing the PUV A treatment m erely r eflect the positive clinical 
response and the diminished inflammatory process, or whether 
they are caused by more direct effects of the radiation on the 
immune system. In the latter case the immunological changes 
could be independent on cutaneous changes or operative in the 
healing process. The latter alternative, however , seems unlikely, 
as the present study did not disclose a ny obvious relationship 
between the cell m ediated immune m echanism s and atopic 
dermatitis. 
The skilled technical assistance of Mrs. Mru'jo Ingman and Mrs. 
Aune Ma nner is gratefully acknowledged. 
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